How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

SVGP-KAN is a library for building interpretable, probabilistic, and scalable neural networks. It merges the architecture of Kolmogorov-Arnold Networks (KANs) with the uncertainty quantification of ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

DNA Ginkgo Bioworks Holdings, Inc.

Process chemistry involves the development and optimization of production processes for chemical compounds, and the scaling up of laboratory reactions, particularly in the pharmaceutical sector. The ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Abstract: Robot interaction control with variable impedance parameters may conform to task requirements during continuous interaction with dynamic environments. Iterative learning (IL) is effective to ...

Abstract: Terrain analysis is critical for the practical application of ground mobile robots in real-world tasks, especially in outdoor unstructured environments. In this paper, we propose a novel ...

Hut 8 shares were up more than 11% in Wednesday’s midday trade after the company announced that it is building an AI data center for Anthropic. Processa Pharmaceuticals' shares were up nearly 95% ...